Dennewill James Robert Jr. 4

What Happened
Dennewill James Robert Jr., Chief Operating Officer of SpyGlass Pharma, was granted a derivative award covering 105,000 shares on February 5, 2026. The Form 4 reports the acquisition price as $0.00 (grant), and the transaction is reported as an award/grant (code A) rather than an open-market purchase or sale. This is a compensation-related award (not an immediate sale) that vests over time per the company plan.

Key Details

• Transaction date: February 5, 2026; filing date: February 9, 2026 (timely — filed on the second business day after the transaction).
• Amount: 105,000 shares (derivative securities); reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the provided filing details.
• Vesting (footnote): Vesting Commencement Date = Feb 5, 2026. 25% of the option vests on the one-year anniversary (Feb 5, 2027), then 1/48th of the total shares vests monthly thereafter. The footnote explicitly refers to these as options subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or immediate disposition was reported.

Context
This filing reflects a time-based equity award (options) intended as executive compensation and retention — the recipient does not receive all shares immediately; they vest over a multi-year schedule. Because it’s an award (not a purchase), it’s primarily a compensation disclosure rather than a personal investment signal.